Speliotes E K, Massaro J M, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study [J]. Hepatology, 2010, 51(6): 1979-1987. [2]Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty liver disease[J]. Dig Dis, 2010, 28(1): 155-161. [3]Laguna J C, Alegret M, Roglans N. Simple sugar intake and hepatocellular carcinoma: epidemiological and mechanistic insight[J]. Nutrients, 2014, 6(12): 5933-5954. [4]Liu Z W, Shao C R, Zhang C J, et al. The SET domain proteins SUVH2 and SUVH9 are required for Pol V occupancy at RNA-directed DNA methylation loci[J]. PLoS Genet, 2014, 10(1): e1003948. [5]Inoue N, Hess K D, Moreadith R W, et al. New gene family defined by MORC, a nuclear protein required for mouse spermatogenesis[J]. Hum Mol Genet, 1999, 8(7): 1201-1207. [6]Moissiard G, Cokus S J, Cary J, et al. MORC family ATPases required for heterochromatin condensation and gene silencing[J]. Science, 2012, 336(6087): 1448-1451. [7]Sanchez-Solana B, Li D Q, Kumar R. Cytosolic functions of MORC2 in lipogenesis and adipogenesis[J]. Biochim Biophys Acta, 2014, 1843(2): 316-326. [8]Lu X. Tied up in loops: positive and negative autoregulation of p53[J]. Cold Spring Harb Perspect Biol, 2010, 2(5): a000984. [9]Vousden K H, Ryan K M. p53 and metabolism[J]. Nat Rev Cancer, 2009, 9(10): 691-700. [10]Xie F, Jia L, Lin M, et al. ASPP2 attenuates triglycerides to protect against hepatocyte injury by reducing autophagy in a cell and mouse model of non-alcoholic fatty liver disease[J]. J Cell Mol Med, 2015, 19(1): 155-164. [11]Castro R E, Ferreira D M, Afonso M B, et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease[J]. J Hepatol, 2013, 58(1): 119-125. [12]Tomita K, Teratani T, Suzuki T, et al. p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice[J]. J Hepatol, 2012, 57(4): 837-843. [13]王涛, 雷增杰, 王斌, 等. ZCWCC1蛋白在L02肝细胞脂肪变性中的表达变化[J]. 第三军医大学学报, 2015, 37(2): 89-94. [14]Ricchi M, Odoardi M R, Carulli L, et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes[J]. J Gastroenterol Hepatol, 2009, 24(5): 830-840. [15]熊吉, 王军, 樊丽琳, 等. Sigma-1受体在非酒精性脂肪性肝病中的表达及意义[J]. 第三军医大学学报, 2011, 33(8): 800-803. [16]Saucedo L J, Edgar B A. Filling out the Hippo pathway[J]. Nat Rev Mol Cell Biol, 2007, 8(8): 613-621. [17]王权, 戚华兵, 王晓凤, 等. 阻断TGF-β/TGF-βRⅠ通路对ATDC5细胞增殖、分化及细胞外基质的影响[J]. 第三军医大学学报, 2013, 35(10): 917-921. [18]Day C. Pathogenesis of steatohepatitis[J]. Best Pract Res Clin Gastroenterol, 2002, 16(5): 663-678. [19]Derdak Z, Villegas K A, Harb R, et al. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease[J]. J Hepatol, 2013, 58(4): 785-791. [20]Hock A K, Vigneron A M, Carter S, et al. Regulation of p53 stability and function by the deubiquitinating enzyme USP42[J]. EMBO J, 2011, 30(24): 4921-4930.
[2]
王军,黄殿静,赖姝婕,等.肝细胞脂肪变性模型中Sec61α的表达及可能作用机制[J].第三军医大学学报,2014,36(08):755. Wang Jun,Huang Dianjing,Lai Shujie,et al.Sec61α expression and its possible role in hepatic steatosis model[J].J Third Mil Med Univ,2014,36(10):755. [2]张勇,陈明亮,高燕翔,等.白藜芦醇通过诱导自噬缓解肝细胞脂肪变性[J].第三军医大学学报,2014,36(21):2178. Zhang Yong,Chen Mingliang,Gao Yanxiang,et al.Resveratrol attenuates steatosis in cultured hepatic cells by inducing autophagy[J].J Third Mil Med Univ,2014,36(10):2178. [3]王涛,雷增杰,王斌,等.ZCWCC1蛋白在L02肝细胞脂肪变性中的表达变化[J].第三军医大学学报,2015,37(02):89. Wang Tao,Lei Zengjie,Wang Bin,et al.Variation of ZCWCC1 protein expression in steatosis of L02 hepatocytes[J].J Third Mil Med Univ,2015,37(10):89.
